Tilray Medical Receives Clearance to Extend Marketing Authorization in Italy
LEAMINGTON, Ont. and CANTANHEDE, Portugal, Sept. 22, 2022 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis company inspiring and enabling the global community to live their best life, today announced that FL Group SRL (“FL Group”), a division of Tilray Medical in Italy, has received approval from the Italian Ministry of Health to import and distribute Tilray THC25 medical cannabis oral solution across the country.
Denise Faltischek, Director of Strategy and Head of International Affairs at Tilray, said: “The extension of our approved authorization to Italy further demonstrates our commitment to being the most responsible, trusted cannabis company and the most market-leading in the world with an innovative and high-quality product portfolio. quality products that meet the needs of the patients and consumers we serve. We remain dedicated and focused on working with regulators in international markets to advocate for responsible cannabis regulation, best practices, and a trusted source of quality products.
In Italy, where medical cannabis authorization is limited, Tilray Medical has an established national pharmaceutical distribution network with FL Group to distribute Tilray’s THC25 medical cannabis oral solution. Patients can obtain prescriptions for Tilray and other medical cannabis products in Italy through their doctor.
Tilray Medical is a leading supplier of EU-GMP certified medical cannabis products in 22 countries with a comprehensive THC and CBD product portfolio. Each medical cannabis product offered by Tilray has been selected to ensure that patients can receive both the highest product quality and consistency in the sourcing of their medical cannabis products.
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering the dignity of patients in need through safe and trusted access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast and Symbios. Tilray went from being one of the first companies to become a licensed producer of medical cannabis in Canada to building the first EU-GMP certified cannabis production facilities in Europe, first in Portugal and then in Germany. Today, Tilray Medical is one of the largest branded suppliers of medical cannabis to patients, doctors, hospitals, pharmacies, researchers and governments, in 22 countries and on five continents.
For more information on medical cannabis and Tilray Medical, visit www.Tilray.com/tilray-medical and follow @tilraymedical on Instagram.
About FL Group
FL Group SRL markets and distributes pharmaceutical, medical, orthopedic and electromedical products in Italy. In 2015, FL Group became one of the first companies authorized by the Italian Ministry of Health to import and distribute medical cannabis. Today, FL Group specializes as a leader in the pharmaceutical distribution of medical cannabis for therapeutic use, pharmaceutical drugs for human and veterinary use, and a traceable supply chain of products for pharmacies of innovative products to meet the needs of its customers across Italy.
For more information about FL Group and to discover the range of products offered, please visit: www.fl-group.it
About Tilray Brands
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global cannabis and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America, changing people’s lives for the better – one person at a time. Tilray Brands fulfills this mission by inspiring and empowering the global community to live their best life and by providing access to products that meet the needs of their mind, body and soul while invoking The well-being. Patients and consumers trust Tilray Brands to deliver a cultured experience of health and well-being through differentiated, high-quality brands and innovative products. A pioneer in cannabis research, cultivation and distribution, Tilray’s unparalleled production platform supports over 20 brands in over 20 countries, including complete cannabis offerings, hemp edibles and craft drinks.
For more information about Tilray brands, visit www.Tilray.com and join the @Tilray conversation.
Certain statements contained in this communication that are not historical facts constitute forward-looking information or forward-looking statements (collectively, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended. , and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “anticipate”, “future”, “should”, “could”, “allow”, “potential”, “envisage”, “believe”, “anticipate”, “estimate, “plan”, “expect”, “intend”, “may”, “project”, “will”, “would” and the negative form of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, objectives, projections or assumptions have been used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, prospects, analyzes or current expectations regarding, among other things: expectations regarding the performance and scale of the Company, including Tilray Medical; and the Company’s ability to expand its offering to patients worldwide, including through Tilray Medical. Many factors could cause actual results, performance or achievements to differ materially from any forward-looking statements, and other risks and uncertainties currently unknown to the Company or that the Company deems immaterial could also cause actual results or actual events that differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see Tilray’s most recently filed annual information sheet and Tilray’s annual report on Form 10-K (and other periodic reports filed with the SEC) of Tilray written with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication, and the Company undertakes no obligation to publicly update these forward-looking statements to reflect new information, subsequent events or otherwise, except as required by securities laws. applicable securities so require.
For more information: